SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Integral Health Asset Management, LLC

CIK 0001773206 · 437 MADISON AVE, 19TH FLOOR, NEW YORK, NY, 10022 · 917-816-1035

Reported Value
$808M
Q2 2023
Positions
73
Filings on Record
27
2019–present window
Filed
Aug 11, 2023
original filing

Summary

Integral Health Asset Management, LLC reported $808M in U.S.-listed holdings across 73 positions for Q2 2023.

Its largest position, CI, represents 6.3% of the portfolio.

Compared with Q1 2023, the fund opened 33 new positions and exited 31.

Portfolio Metrics

Turnover
+31.8%
vs prior filed quarter
Top-10 Concentration
+34.2%
share of reported value
Largest Position
+6.3%
The Cigna
New / Exited
33 / 31
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $257MQ4 ’19Q1 ’20: $227MQ2 ’20: $334MQ3 ’20: $327MQ4 ’20: $336MQ4 ’20Q1 ’21: $350MQ2 ’21: $363MQ3 ’21: $348MQ4 ’21: $361MQ4 ’21Q1 ’22: $384MQ2 ’22: $486MQ3 ’22: $515MQ4 ’22: $476MQ4 ’22Q1 ’23: $496MQ2 ’23: $808MQ3 ’23: $722MQ4 ’23: $734MQ4 ’23Q1 ’24: $1.1BQ2 ’24: $1.1BQ3 ’24: $889MQ4 ’24: $1.2BQ4 ’24Q1 ’25: $940MQ2 ’25: $1.1BQ3 ’25: $1.5BQ4 ’25: $2.0BQ4 ’25Q1 ’26: $2.1Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 82.1%Other: 11.8%ADR: 6.2%
  • Common Stock · 82.1% · $663M
  • Other · 11.8% · $95M
  • ADR · 6.2% · $50M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CITHE CIGNA GROUPNEW+180.0K180.0K+$51M$51M
ZBHZIMMER BIOMET HOLDINGS INCNEW+300.0K300.0K+$44M$44M
NOVO-NORDISK A SNEW+250.0K250.0K+$40M$40M
MCKMCKESSON CORPNEW+72.0K72.0K+$31M$31M
THCTENET HEALTHCARE CORPNEW+232.0K232.0K+$19M$19M
MLTXMOONLAKE IMMUNOTHERAPEUTICSNEW+300.0K300.0K+$15M$15M
EHCENCOMPASS HEALTH CORPNEW+220.0K220.0K+$15M$15M
LLYLILLY ELI & CONEW+30.0K30.0K+$14M$14M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CITHE CIGNA GROUPhistory →COM6.25%$51M180.0K
2ZBHZIMMER BIOMET HOLDINGS INChistory →COM5.41%$44M300.0K
3INSPINSPIRE MED SYS INChistory →COM4.14%$33M103.0K
4MCKMCKESSON CORPhistory →COM3.81%$31M72.0K
5BSXBOSTON SCIENTIFIC CORPhistory →COM3.12%$25M466.0K
6CYTKCYTOKINETICS INChistory →COM NEW2.63%$21M650.0K
7COOPER COS INCCOM NEW2.47%$20M52.0K
8THCTENET HEALTHCARE CORPhistory →COM NEW2.34%$19M232.0K
9PKNREVVITY INChistory →COM2.06%$17M140.0K
10ARGXARGENX SEhistory →SPONSORED ADR1.93%$16M40.0K
11MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD1.89%$15M300.0K
12EHCENCOMPASS HEALTH CORPhistory →COM1.84%$15M220.0K
13GHGUARDANT HEALTH INChistory →COM1.83%$15M412.0K
14HO1HOLOGIC INChistory →COM1.75%$14M175.0K
15LLYLILLY ELI & COhistory →COM1.74%$14M30.0K
16CNCCENTENE CORP DELhistory →COM1.67%$13M200.0K
17ABBVABBVIE INChistory →COM1.67%$13M100.0K
18ELVELEVANCE HEALTH INChistory →COM1.65%$13M30.0K
19SDGRSCHRODINGER INChistory →COM1.64%$13M265.0K
20ZNTLZENTALIS PHARMACEUTICALS INChistory →COM1.57%$13M450.0K
21GSKGSK PLChistory →SPONSORED ADR1.54%$12M350.0K
22ISRGINTUITIVE SURGICAL INChistory →COM NEW1.52%$12M36.0K
23RETAEURREATA PHARMACEUTICALS INChistory →CL A1.51%$12M120.0K
24HCAHCA HEALTHCARE INChistory →COM1.50%$12M40.0K
25DHRDANAHER CORPORATIONhistory →COM1.49%$12M50.0K
26JNJJOHNSON & JOHNSONhistory →COM1.48%$12M72.0K
27VKTXVIKING THERAPEUTICS INChistory →COM1.47%$12M730.0K
28VTYXUSDVENTYX BIOSCIENCES INChistory →COM1.42%$11M350.0K
29SGRYSURGERY PARTNERS INChistory →COM1.39%$11M250.0K
30NVSNNOVARTIS AGhistory →SPONSORED ADR1.29%$10M103.0K
31REPLREPLIMUNE GROUP INChistory →COM1.28%$10M445.0K
32PENPENUMBRA INChistory →COM1.28%$10M30.0K
33ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.22%$10M52.0K
34RVMDREVOLUTION MEDICINES INChistory →COM1.18%$10M356.0K
35INARI MED INCCOM1.12%$9M155.0K
36ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM1.11%$9M142.0K
37ALKERMES PLCSHS1.10%$9M284.0K
38RLAYRELAY THERAPEUTICS INChistory →COM1.09%$9M700.0K
39NTLAINTELLIA THERAPEUTICS INChistory →COM1.04%$8M206.0K
40EXKEXACT SCIENCES CORPhistory →COM1.02%$8M88.0K
41TEVATEVA PHARMACEUTICAL INDS LTDSPONSORED ADS0.93%$8M1.00M
42KRYSKRYSTAL BIOTECH INCCOM0.90%$7M62.0K
43PTCTPTC THERAPEUTICS INCCOM0.88%$7M174.0K
44LFSTLIFESTANCE HEALTH GROUP INCCOM0.87%$7M773.0K
45MEDTRONIC PLCSHS0.87%$7M80.0K
46APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.81%$7M72.0K
47RVNCEURREVANCE THERAPEUTICS INCCOM0.78%$6M250.0K
48TGTXTG THERAPEUTICS INCCOM0.77%$6M250.0K
49SIBNSI-BONE INCCOM0.76%$6M227.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.1B90May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B86Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.5B76Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.1B72Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$940M81May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.2B83Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$889M66Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.1B72Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.1B80May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$734M69Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$722M65Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$808M73Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$496M71May 9, 202313F-HRchanges · EDGAR ↗
Q4 2022$476M61Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$515M65Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$486M65Aug 3, 202213F-HRchanges · EDGAR ↗
Q1 2022$384M71May 12, 202213F-HRchanges · EDGAR ↗
Q4 2021$361M71Feb 2, 202213F-HRchanges · EDGAR ↗
Q3 2021$348M70Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$363M71Aug 30, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$350M69May 10, 202113F-HRchanges · EDGAR ↗
Q4 2020$336M57Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$327M72Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$334M60Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$227M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$257M50Feb 13, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.